Plain-English translation of NCT07104721 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new cell therapy called YTS109 cells in patients whose autoimmune diseases—such as lupus, lupus kidney disease, or lupus-related low platelet counts—have not improved with standard medicines. You would receive a single infusion of this medication, and researchers would carefully monitor you to see if it is safe and whether it helps reduce your symptoms.
Many patients with severe autoimmune diseases do not get better even after trying multiple standard treatments, and their conditions continue to get worse. This trial exists to explore whether this new cell-based treatment could help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital to receive a single infusion of YTS109 cells into your bloodstream. The researchers would then monitor you closely over time—through blood tests, clinical exams, and symptom assessments—to track whether the treatment is safe and whether your autoimmune disease improves. The study is designed to be smaller and more cautious at first, starting with lower cell doses and increasing them gradually if safety is confirmed.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China